Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993–2007

Barbara Tempalski 1*, Charles M. Cleland 2, Leslie D. Williams 1, Hannah L. F. Cooper 3 and Samuel R. Friedman 1,4

Abstract

Background: Our previous research has found low and stable mean drug treatment coverage among people who inject drugs (PWID) across 90 large US metropolitan statistical areas (MSAs) during 1993–2002. This manuscript updates previous estimates of change in drug treatment coverage for PWID in 90 MSAs during 1993–2007.

Methods: Our drug treatment sample for calculating treatment coverage includes clients enrolled in residential or ambulatory inpatient/outpatient care, detoxification services, and methadone maintenance therapy at publicly- and privately-funded substance abuse agencies receiving public funds. Coverage was measured as the number of PWID in drug treatment, calculated by using data from the Substance Abuse and Mental Health Service Administration, divided by numbers of PWID in each MSA. We modeled change in drug treatment coverage rates using a negative binomial mixed-effects model. Fixed-effects included an intercept and a main effect for time. Incidence rate ratios (IRR) were calculated for both average change from 1993 to 2007 and MSA-specific estimates of change in coverage rates.

Results: On average over all MSAs, coverage was low in 1993 (6.1%) and showed no improvement from 1993 to 2007 (IRR = 0.99; 95% CI, 0.86, 1.2). There was modest variability across MSAs in coverage in 1993 (log incidence rate SD = 0.36) as well as in coverage change from 1993 to 2007 (log IRR SD = 0.32). In addition, results indicate significant variability among MSAs in coverage.

Conclusions: Inadequate treatment coverage for PWID may produce a high cost to society in terms of the spread of overdose mortality and injection-related infectious diseases. A greater investment in treatment will likely be needed to have a substantial and more consistent impact on injection drug use-related harms. Future research should examine MSA-level predictors associated with variability in drug treatment coverage.

Keywords: People who inject drugs, Opioids, Drug treatment coverage, Change over time, Metropolitan statistical areas

* Correspondence: templaski@ndri.org

1 Institute for Infectious Disease Research, NDRI, Inc., 71 West 23rd Street, 4th Floor, New York, NY 10010, USA

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
In the United States, the misuse of and addiction to opioids – including prescription opioid analgesics, heroin, and synthetic opioids – is a serious national problem that affects public health as well as social and economic welfare [1–5]. In 2015, over 33,000 Americans died as a result of an opioid-related overdose, another 2.5 million people suffered from substance use disorders related to prescription opioid analgesics, heroin, and synthetic opioids [4, 6–10]. Meanwhile, the cost of prescription opioids, combined with their shrinking availability, has led opioid users to the cheaper and more readily available alternative of heroin [4, 11–14]. This trend has led to a wave of new young heroin injectors, escalating the risk of HIV and HCV and drug-related mortality among this cohort [12, 13, 15–18]. Given the magnitude of this ongoing public health epidemic, it is critical to understand the availability and coverage of drug treatment services for those in need of them.

Significance of understanding drug treatment coverage rates among PWID
Drug treatment for PWID is effective in reducing harms and improving users’ health outcomes [19–23]. Evidence-based drug treatment, such as methadone maintenance therapy and buprenorphine, can also address a broad range of social and public health problems [17, 19, 21, 23–25], especially when programs provide access to AIDS education and prevention programs, HIV and HCV testing, and contact with health care systems to those clients already infected with HIV [20–23, 25]. Adequate access and expansion to effective treatment and medication assisted therapies for opioid dependence has led to improved antiretroviral therapy (ART) adherence and decreases in morbidity among PWID [17, 25–32].

Additionally, research on the effectiveness of drug treatment indicates that increased length of time in treatment is associated with lower rates of needle sharing and HIV seropositivity [18, 23, 25, 27–30]. Treatment may also be related to reductions in overdose, illicit drug use, and unemployment among drug users in general, although these effects may vary by treatment modality and access to treatment service facilities [5, 23, 26, 31, 32]. In view of such evidence, public health would clearly benefit if drug treatment were widely available to drug injectors.

Prior research on treatment coverage among PWID estimated the number of injectors and the extent of treatment coverage in 90 US metropolitan statistical areas (MSAs) for 1993–2002, reporting that drug treatment coverage was low in 1993 (mean 6.7%; median 6.0%) and decreased slightly in 2002 (mean of 8.3%; median of 8.0%) [33]. Here we present a brief update on drug treatment coverage rates among PWID from 1993 to 2007 in 90 MSAs in the USA.

Methods and data
Overview
We define treatment coverage as the ratio of PWID in treatment to total PWID in each MSA. Percentage of PWID in treatment for each year from 1993 to 2007 (excluding years 1994, 1999, and 2001) was calculated using data on drug treatment entries and reported injection at drug treatment intake from the Substance Abuse and Mental Health Service Administration (SAMHSA) [34–37], and population estimates of PWID from our previous research [38].

Unit of analysis and sample
As previously noted in Tempalski et al. (2010) [33], the unit of analysis in this study is the MSA. The US Census Bureau and Office of Management and Budget define an MSA as a set of contiguous counties that include one or more central cities of at least 50,000 people that collectively form a single, cohesive socioeconomic unit, defined by inter-county commuting patterns and socioeconomic integration [39]. MSAs are meaningful epidemiologic units within which to study PWID and services designated for them [40].

Calculating number of PWID
Tempalski and colleagues [38] first estimated the number of PWID in the US each year from 1992 to 2007 and then apportioned these estimates to MSAs using multiplier methods. Four different types of data indicating

Table 1 Description of Data Sources Utilized to Calculate Drug Treatment Coverage Rates

| Description of Data Sources Utilized to Calculate Drug Treatment Coverage Rates | 1) Proportion of treatment entrants who indicated that they injected substances intravenously in each MSA and year (1993–2007) as reported by the TreatmentEpisode Data Set (TEDS) [44]; 2) Total number of drug users in drug treatment as of October 1 of each year reported by the Uniform Facility Data Set (UFDS) for 1993, 1995, 1996–1998 [45, 46] and the National Survey of Substance Abuse Treatment Services (N-SSATS) for 2000, 2002–2007 [37]; 3) Total estimated number of PWID in each MSA and year (1993–2007) as calculated and reported by Tempalski and colleagues [38] |
|---|---|
|   | 1) Proportion of treatment entrants who indicated that they injected substances intravenously in each MSA and year (1993–2007) as reported by the TreatmentEpisode Data Set (TEDS) [44]; 2) Total number of drug users in drug treatment as of October 1 of each year reported by the Uniform Facility Data Set (UFDS) for 1993, 1995, 1996–1998 [45, 46] and the National Survey of Substance Abuse Treatment Services (N-SSATS) for 2000, 2002–2007 [37]; 3) Total estimated number of PWID in each MSA and year (1993–2007) as calculated and reported by Tempalski and colleagues [38] |
|   | *These data do not capture medication-assisted treatment (MAT) operating out of private medical offices. Additionally, we need to acknowledge much of any system response to the opioid epidemic would have taken place after 2007, and so our data would miss those more recent changes*
|   | *Our drug treatment coverage estimates are based on the number of PWID in an MSA. Current data available for PWID are up through 2007* |
Calculating drug treatment coverage rates

We define treatment coverage as the ratio of PWID in treatment to PWID in the MSA. Our drug treatment sample for calculating treatment coverage includes clients enrolled in residential or ambulatory inpatient/outpatient care, detoxification services, and methadone maintenance therapy at publicly- and privately-funded substance abuse agencies receiving public funds. These are facilities licensed, certified, or otherwise approved by State substance abuse agencies to provide substance abuse treatment. Buprenorphine patients are not included in these data unless their buprenorphine is provided by one of these agencies.

Treatment coverage for PWID is estimated using TEDS and UFDS/N-SSATS. Here, the difficulty is that neither data set provides an estimate of the number of clients who inject drugs. UFDS/N-SSATS does provide data on the number of clients in these treatment services. We adjust these estimates by multiplying them by the proportion of treatment entrants who inject drugs, which can be calculated from TEDS data. The following equation calculates drug treatment coverage rates:

\[ C_{ijt} = \frac{A_{ijt} \cdot B_{ijt} \cdot C_{ijt}}{E_{ijt}} \]

where,
- \( A_{ijt} \) = treatment coverage rate for an MSA \( j \) in year \( t \); 
- \( B_{ijt} \) = number of PWID entering drug treatment as reported by TEDS for an MSA \( j \) in year \( t \); 
- \( C_{ijt} \) = number of PWID and number of non-injectors \(^1\) entering drug treatment as reported by TEDS for an MSA \( j \) in year \( t \); 
- \( D_{ijt} \) = number of drug users in drug treatment reported by UFDS/N-SSATS for an MSA \( j \) in year \( t \); and, 
- \( E_{ijt} \) = estimated number of PWID as estimated by Tempalski et al. [38] for an MSA \( j \) in year \( t \).

First, the TEDS data series identifies the number and attributes of clients who enter substance abuse treatment programs that receive any state and federal funding. From TEDS, we calculated the proportion of treatment entrants who reported they injected drugs as a mode of administration. Our second SAMHSA data source comes from the annual census of drug treatment facilities originally referred to as the Uniform Facility Data Set (UFDS) – but since renamed the National Survey of Substance Abuse Treatment Services (N-SSATS). UFDS/N-SSATS data measure client characteristics and use of privately- and publicly-funded substance abuse treatment programs in the U.S. on October 1 for each year. However, UFDS/N-SSATS data were unavailable for 1992, 1994, 1999, and 2001. As a result of this limited availability, our coverage estimates were only created for years where data were available. Thus, our final drug treatment coverage estimates only provide data for 1993, 1995, 1996–1998, 2000, and 2002–2007.

Negative binomial mixed model for estimating change in drug treatment coverage rates

We modeled change in drug treatment coverage rates using a negative binomial mixed-effects model. Fixed-effects included an intercept and a main effect for time. Time was coded such that the intercept captured the coverage rate in 1993, and the time main effect captured the increase in coverage rate from 1993 to 2007. The natural logarithm of PWID population size in each MSA was included as an offset. Both the intercept and the time main effect

Table 2 Descriptive statistics of estimated PWID drug treatment coverage rates

| Year | Mean | SD  | Min | Q25 | Median | Q75 | Max |
|------|------|-----|-----|-----|--------|-----|-----|
| 1993 | 6.75 | 3.70| 0.80| 4.20| 5.60   | 9.40| 16.40|
| 1995 | 6.71 | 4.16| 0.90| 3.60| 5.65   | 9.70| 20.60|
| 1996 | 6.66 | 4.01| 0.90| 3.40| 5.05   | 9.70| 18.10|
| 1997 | 6.87 | 5.47| 1.10| 3.00| 5.30   | 9.70| 28.90|
| 1998 | 8.22 | 6.42| 0.60| 3.40| 5.90   | 12.00| 36.00|
| 2000 | 7.87 | 5.81| 0.50| 3.40| 6.05   | 10.30| 31.80|
| 2002 | 8.70 | 5.38| 1.00| 4.50| 7.40   | 10.90| 26.80|
| 2003 | 7.31 | 5.36| 0.90| 3.20| 5.70   | 9.20| 27.30|
| 2004 | 6.67 | 5.15| 0.90| 3.20| 5.30   | 8.10| 29.40|
| 2005 | 6.50 | 4.99| 1.00| 2.80| 4.85   | 8.30| 22.70|
| 2006 | 6.48 | 4.48| 0.90| 2.90| 5.10   | 8.20| 22.30|
| 2007 | 6.40 | 4.51| 0.90| 3.20| 5.15   | 8.90| 19.70|

\(^1\)Percent in treatment
were allowed to vary randomly across MSAs, yielding MSA-specific estimates of change in addition to average change over all MSAs. Incidence rate ratios (IRR) were calculated for both average change from 1993 to 2007 and MSA-specific estimates of change in coverage rates. The model was fit using PROC GLIMMIX of SAS (Version 9.3). [45]

Results
Descriptive statistics
As depicted in Table 2 and in Fig. 1, coverage overall changed little from 1993 to 2007. Mean drug treatment coverage was only 6.4% (standard deviation 4.5%; interquartile range 3.2%-8.9) in 2007, reflecting a slight decrease from 6.7% in 1993 (standard deviation 3.7%; interquartile range 4.2–9.4%). Median treatment coverage decreased from 5.6% in 1993 to 5.2% in 2007.

Incidence rate ratios of change
Table 3 shows the fixed-effect of time estimates in coverage change from 1993 to 2007 across MSAs indicated a stable rate of overall drug treatment coverage over time (IRR: 0.99, 95% CI: 0.86, 1.25).

While the average change in rate over the expanded study period is close to zero, there is substantial variation in rate of change across MSAs. Estimated from the mixed-effects negative binomial model, the standard deviation of log incidence rate ratios was SD = 0.32. MSA-specific IRR estimates of change in coverage rates, which also convey this variability in coverage change over MSAs, are displayed in Fig. 2.

Forty-eight (53%) of the MSAs had an increase (IRR > 1.0) in treatment coverage across the 1993–2007 period. Of those, only eighteen were statistically significant at \( p \leq 0.05 \) (Albany-Schenectady, NY; Birmingham, AL; Charlotte-Gastonia-Rock-Hill, NC-SC; Cincinnati, OH-KY-IN; Dayton-Springfield, OH; Detroit, MI; Greenville-Spartanburg, SC; Jersey City, NJ; Knoxville, TN; Louisville, KY-IN; Monmouth-Ocean, NJ; New York, NY; Newark, NJ; Pittsburgh, PA; Raleigh-Durham-Chapel Hill, NC; Richmond-Petersburg, VA; Rochester, NY; Wilmington-Newark, DE-MD).

In addition, forty-one (45%) of the MSAs had a decrease (IRR < 1.0) in treatment coverage across the study period. Eighteen MSAs exhibited a statistically significant decrease in coverage (Bakersfield, CA; Charleston-North Charleston, SC; Dallas, TX; Fresno, CA; Honolulu HI; Houston, TX; Los Angeles-Long Beach, CA; Oakland, CA; Riverside-San Bernardino, CA; San Francisco, CA; San Diego, CA; Stockton-Lodi, CA; Sacramento, CA; Tacoma, WA; Toledo, OH; Tulsa, OK; Youngstown-Warren, OH).

Discussion
Drug treatment services in the US have largely operated as an independent part of the overall health care system, with unique methods of funding and service delivery. The variability in funding and service delivery varies

![Fig. 1 Mean and Median Estimates of Drug Treatment Coverage Rates, 1993-2007](image-url)
greatly among US states and even among cities within the same state [46, 47]. Meanwhile, US conservative policies and attitudes toward embracing alternative approaches to treatment, such as harm reduction and opioid agonist therapy, lags well behind much of Western Europe and other regions [33, 48]. As a result, alternative treatments for opioid use disorder such as opioid agonist therapy (i.e., methadone and/or buprenorphine) have not increased to match demand. Such factors highlight the heterogeneous situation in the US with respect to treatment coverage and the fact that treatment provision remains insufficient in so many areas in the US [46, 47, 49, 50].

As previously reported by Tempalski and colleagues [33, 40], treatment coverage for PWID in US MSAs was far below international standards. Some European Union countries, for example, maintain coverage levels of 65% or higher (i.e., France 80%) are in comparison to US coverage rates [48].

Our current estimates show that the average coverage rate change was essentially zero (IRR: 0.99), suggesting no effective, systematic, or country-wide expansion of treatment coverage over the study period. There was however significant variation in coverage rates and coverage rate changes among MSAs. Such variation may be explained by MSA-level factors we have yet to investigate.

Low availability of drug treatment coverage has many public health implications for the US opioid epidemic. In recent years, nonmedical use of prescription opioids has not only been increasing [1–7], but has also been found to be a significant risk factor for heroin use (in particular for injection-related use), unintentional opioid-related overdose, and transmission of HIV and HCV [7–9, 11–14, 16–18], underscoring the need for expanding prevention and drug treatment efforts. Drug treatment coverage will need to increase in order to adequately address need and to curb the recent rise in morbidity and mortality associated with the rise in the misuse of and addiction to opioids.

**Conclusion**

Our findings highlight the lack of increase in the ratio between the availability of PWID treatment services and the number of PWID who want or could benefit from drug abuse treatment. Given that drug treatment is effective in reducing harms, a greater investment in drug treatment and the broader services offered at treatment centers must be made to contribute to reducing injection drug use and associated harms. Future research should examine what policy and structural changes affect variations and changes in treatment coverage - and, in particular, what combinations of MSA-level factors lead to increases in treatment coverage.

**Endnotes**

1In TEDS, non-injectors are defined as clients who use illicit drugs via other routes of administration than injection, such as oral, inhalation, or smoked.

**Abbreviations**

AIDS: Acquired immune deficiency syndrome; AL: Alabama; ART: Antiretroviral therapy; CA: California; CDC: Centers for Disease Control; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; KY-IN: Kentucky-Indiana; MI: Michigan; MSAs: US metropolitan statistical areas; NC: North Carolina; NJ: New Jersey; N-SSATS: National Survey of Substance Abuse Treatment Services; NY: New York; OH: Ohio; PA: Pennsylvania; PWID: People who inject drugs; SAMHSA: Substance Abuse and Mental Health Service Administration; TEDS: Treatment Episode Data Set; UFDS: Uniform Facility Data Set; US: United States; VA: Virginia

**Acknowledgements**

We kindly acknowledge from the Department of Psychiatry at the University of California San Francisco, Professor’s Elinore F. McCance-Katz and James L. Sorensen; Professor Joseph R. Guydish from Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco; Dr’s Darren Urada and Richard A. Rawson at the UCLA Integrated Substance Abuse Programs in Los Angeles, CA; and Dr. Alex H. Kral Director, Urban Health Program at RTI International, San Francisco, CA for their knowledge and reflection of drug treatment coverage for PWID in the State of California. The authors also
thank Mr. Lucas Wessing from the European Monitoring Centre for Drugs and Drug Addiction in Lisbon, Portugal for his thoughtful discussion and knowledge regarding drug treatment coverage in the European Union and elsewhere. We thank from the Substance Abuse and Mental Health Services Administration, Dr. Cathie E. Alderks for her assistance on SAMHSA drug treatment data issues.

**Funding**
This project was supported by the National Institute of Drug Abuse (ROI DA037568; Metropolitan Trajectories of HIV Epidemics and Responses in US Key Populations and, P30DA011041; Center for Drug Use & HIV Research).

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**
BT was responsible for data acquisition, analysis, and interpretation; and the writing of the article. CMC contributed to the analysis and interpretation of the data, and the writing of the article. SRF contributed to the conception of the analysis and the writing. LDW, HLFC contributed to the writing of the article. BT, CMC, SRF, LDW, and HLFC read and approved the final manuscript.

**Ethics approval and consent to participate**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests. Each author has contributed to the conception and design of the work, the acquisition of data or the analysis of the data in a manner substantial enough to take public responsibility for it. In addition, each author believes that the paper represents valid work and has reviewed the final version of the manuscript and approves consent for publication.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**
1Institute for Infectious Disease Research, NDRI, Inc., 71 West 23rd Street, 4th Floor, New York, NY 10010, USA. 2New York University College of Nursing, New York, NY, USA. 3Rollins School of Public Health, Emory University, Atlanta, GA, USA. 4Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.

Received: 28 February 2018 Accepted: 2 July 2018
Published online: 09 August 2018

**References**

1. Olsen Y. The CDC guideline on opioid prescribing rising to the challenge. JAMA. 2016;315:1577–9.
2. Paulozzi LJ, Strickler G, Kreiner PW, Koris CM. Controlled substance prescribing patterns–prescription behavior surveillance system, eight states, 2013. MMWR. 2015;64:1–14.
3. Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty. U.S., 2007–2012. Am J Prev Med. 2015;49:409–13.
4. Cicero TJ, Ellis MS, Harvey J. Shifting patterns of prescription opioid and heroin abuse in the United States. New Eng J Med. 2015;373:1789–90.
5. Florence C, Luo F, Xu L, Zhou C. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016;54
6. Diaz RC, Suratt HL, Cicero TJ, Parrino MW, Severson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States, New Eng J Med. 2015;372:241–8.
7. Rudd RA, Seth P, David F, Solloll L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR. 2016;65:1445–52.
8. Giwa Baumbllrt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA. 2014;174:796–801.
9. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS data brief no 166. Hyattsville, MD: National Center for Health Statistics; 2014.
10. Hedegaard H, Warner M, Minnho AM. Drug overdose deaths in the United States, 1999-2015. NCHS data brief no 273. Hyattsville, MD: National Center for Health Statistics; 2017.
11. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. New Eng J Med. 2016;374:154–63.
12. Carlson RG, Nahhas RW, Martins SS, Danuilaetebl R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study. Drug Alcohol Depend. 2016;160:127–34.
13. Peavy KM, Banta-Green CJ, Kingston S, Hannahan M, Merrill JO, Coffin PO. “Hooked on” prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients. J Psychoactive Drugs. 2012;44:259–65.
14. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarrone D. ‘‘Every never I ever said came true’: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25:557–66.
15. Gerdã M, Gaidus A, Keyses KM, Ponicki W, Martins S, Galea S, Grunewald P. Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas. Addiction. 2017;112:103–112.
16. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmeteer N, Taylor A, Bruneau J, Hickman M. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:CD012021.
17. MacArthur GJ, Minozzi S, Martini N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMI. 2012;345:e954.
18. Abdul-Quader AS, Feeleymer J, Modi S, Stone ES, Brinceno A, Semaan S, Horvath T, Kennedy GE, Des Jarlais DC. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behavior. 2013;17:2878–92. Metzger DS, Woody GE, O’Brien CP. Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr 2010, 55:332–36.
19. World Health Organization: Effectiveness of drug dependence treatment in preventing HIV among injecting drug users: evidence for action technical paper and policy brief. 2005. Accessed 1 Mar 2010.
20. Des Jarlais DC, Pinkerton S, Hagan H, Guardino V, Feeleymer J, Cooper H, Hatzakis A, Uuskula A. 30 years on selected issues in the prevention of HIV among injectors who inject drugs. Adv Prev Med. 2013;2013:Article ID 943672.
21. Mathers BM, Degenhardt L, Al H, Wiessing L, Hickman M, Mattick RP, Myers B, Ambekar A, Strathdee SA. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28.
22. Simpson DD, Flynn PM. Drug abuse treatment outcome studies (DATOS): A national evaluation of treatment effectiveness. In: Fisher G, Roget N, editors. Encyclopaedia of substance abuse prevention, treatment, and recovery. Thousand Oaks, CA: Sage Publishing; 2008. p. 395–7.
23. Artken CL, Johanson C, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abus Treat. 2010;39:96–104.
24. Lert F, Kazatchkin MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy. 2007;19:255–61.
25. Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, Krishna T, Teshale EH, Paz-Bailey G. HIV infection and risk, prevention, and testing behaviors among injecting drug users – national HIV behavioral surveillance system, 20 U.S. cities, 2009. MMWR. 2014;63:1–51.
26. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, Hogg RS, Montanier JS, Wood E. Methadone maintenance therapy for preventing hepatitis C transmission in people who inject drugs. Addiction. 2010;105:907–13.
27. Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancil L, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis. 2006;43(S4):S178–83.
28. Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K, Dong H, Kerr T, Wood E, Milloy MJ. Dose–response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. Addiction. 2015;110:1330–9.

29. Spire B, Lucas GM, Cameri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST): Int J Drug Policy. 2007; 18:626–70.

30. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214–26.

31. Henkel D. Unemployment and substance use: a review of the literature 1990-2010. Curr Drug Abuse Rev. 2011;4:24–27.

32. Wilson DP, Donald B, Shatock AJ, Wilson D, Frazer-Hunt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:552–51.

33. Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR. Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy. 2010;5:23.

34. Department of Health and Human Services. Subst Abus and Mental Health Services Administration, Office of Applied Studies: Treatment episode data set (TEDS) 1992–2008: [United States] [Computer file]. Ann Arbor, MI: Synectics for Management Decisions, Incorporated. Inter-university Consortium for Political and Social Research; 2010.

35. Department of Health and Human Services, Subst Abus and Mental Health Services Administration, Office of Applied Studies: Uniform Facility Data Set (UFDS) 1993–1995: [United States] [Computer file]. Ann Arbor, MI: Synectics for Management Decisions, Incorporated. Inter-university Consortium for Political and Social Research 1999.

36. Department of Health and Human Services. Substance abuse and mental health services administration, Office of Applied Studies: uniform facility data set (UFDS) 1997–1998: [United States] [computer file]. 2nd ICPSR version ed. Ann Arbor, MI: Synectics for Management Decisions, Incorporated. Inter-university Consortium for Political and Social Res; 2004.

37. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: National Survey of substance abuse treatment services (N-SSATS) 2000–2008: [United States] [computer file]. 3rd ICPSR version ed. Ann Arbor, MI: Synectics for Management Decisions, Incorporated. Inter-university Consortium for Political and Social Res; 2010.

38. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, Lamsky A, West BS, Friedman SR. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One. 2013;8:e64789.

39. Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical areas. Fed Register. 2000;65:8228–8240.

40. Friedman SR, Tempalski B, Brady J, Friedman R, Flom PL, McGrath MM, Gostnell K, Des Jarlais DC. Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States. Int J Drug Policy. 2007;18:475–85.

41. Centers for Disease Control and Prevention. HIV counseling and testing in publicly funded sites. Atlanta, GA: Centers for Disease Control and Prevention; 2010.

42. Centers for Disease Control and Prevention. AIDS surveillance data. Atlanta, GA: Centers for Disease Control and Prevention; 2010.

43. Holmberg S. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–5.

44. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, Friedman R, Flom PL. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004; 81:377–400.

45. SAS Institute. SAS/STAT® 9.3 User’s guide. Cary, NC: SAS Institute; 2011.

46. Bums RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, et al. Policies supporting opioid agonist therapy of opioid use disorders: the evolution of state policies from 2004 to 2013. Subst Abus. 2016;37:63–9.

47. Sharma A, Kelly SM, Mitchell SG, Gtzyczynski J, O’Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19:35.

48. European Monitoring Centre for Drugs and Drug Addiction Health and social responses to drug problems: a European guide. Publications Office of the European Union, Luxembourg, 2017.

49. Dick AW, Pacula RL, Gordon AJ, et al. Increasing potential access to opioid agonist treatment in U.S Treatment Shortage Areas. Health affairs (Project Hope). 2015;34:1028–34.

50. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff. 2011;30:1425–33.